BELLICUM PHARMACEUTICALS INC's ticker is BLCM and the CUSIP is 079481107. A total of 81 filers reported holding BELLICUM PHARMACEUTICALS INC in Q4 2015. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $378,000 | -86.4% | 112,079 | -88.2% | 0.00% | -89.2% |
| Q4 2018 | $2,784,000 | -53.1% | 953,368 | -1.0% | 0.04% | -45.6% |
| Q3 2018 | $5,933,000 | -13.0% | 963,148 | +4.3% | 0.07% | -17.1% |
| Q2 2018 | $6,818,000 | +1141.9% | 923,824 | +1004.4% | 0.08% | +1071.4% |
| Q1 2018 | $549,000 | +45.6% | 83,649 | +174.0% | 0.01% | +16.7% |
| Q1 2017 | $377,000 | -9.4% | 30,525 | 0.0% | 0.01% | 0.0% |
| Q4 2016 | $416,000 | -31.5% | 30,525 | 0.0% | 0.01% | -33.3% |
| Q3 2016 | $607,000 | +36.1% | 30,525 | -11.3% | 0.01% | +28.6% |
| Q2 2016 | $446,000 | +42.9% | 34,417 | -3.2% | 0.01% | +40.0% |
| Q1 2016 | $312,000 | -39.4% | 35,569 | +40.1% | 0.01% | -28.6% |
| Q4 2015 | $515,000 | +39.9% | 25,394 | +0.4% | 0.01% | +40.0% |
| Q3 2015 | $368,000 | -31.6% | 25,304 | 0.0% | 0.01% | -16.7% |
| Q2 2015 | $538,000 | – | 25,304 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 918,000 | $11,328,000 | 4.35% |
| EMORY UNIVERSITY | 164,607 | $2,031,000 | 1.92% |
| Monashee Investment Management LLC | 160,000 | $1,974,000 | 0.79% |
| UNIVERSITY OF NOTRE DAME DU LAC | 210,260 | $2,595,000 | 0.65% |
| CORRADO ADVISORS, LLC | 83,622 | $1,032,000 | 0.59% |
| Foresite Capital Management II, LLC | 105,000 | $1,296,000 | 0.56% |
| Baker Brothers Advisors | 5,032,313 | $62,099,000 | 0.51% |
| SPHERA FUNDS MANAGEMENT LTD. | 200,000 | $2,468,000 | 0.48% |
| Clearline Capital LP | 55,200 | $681,000 | 0.32% |
| LMR Partners LLP | 270,594 | $3,339,000 | 0.32% |